Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
9. februar 2018 oppdatert av: National Cancer Institute (NCI)
A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and 1-3 Brain Metastases
This randomized phase III trial is studying whole-brain radiation therapy and stereotactic radiosurgery with or without temozolomide or erlotinib to see how well they work compared to whole-brain radiation therapy and stereotactic radiosurgery in treating patients with brain metastases secondary to non-small cell lung cancer.
Radiation therapy uses high-energy x-rays to kill tumor cells.
Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue.
Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die.
Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by blocking blood flow to the tumor.
It is not yet known whether radiation therapy and stereotactic radiosurgery are more effective with or without temozolomide or erlotinib in treating brain metastases.
Studieoversikt
Status
Avsluttet
Forhold
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Compare survival in patients with non-small cell lung cancer and brain metastases treated with whole brain radiotherapy and stereotactic radiosurgery with vs without temozolomide or erlotinib.
SECONDARY OBJECTIVES:
I. Compare time to CNS progression in patients treated with these regimens. II. Compare quality-adjusted survival in patients treated with these regimens. III. Compare 3-month quality of life in patients treated with these regimens. IV. Compare the 6-month performance status of patients treated with these regimens.
V. Compare 6-month steroid dependence in patients treated with these regimens. VI. Compare cause of death (neurologic vs other) in patients treated with these regimens.
VII. Determine the effects of non-protocol chemotherapy in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age and the presence of extracranial metastases (< 65 years old AND no extracranial metastases vs ≥ 65 years old OR extracranial metastases), number of metastases (1 vs 2 or 3), and extent of extracranial disease (none vs present). Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19. Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
ARM II: Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21. Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5. Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
ARM III: Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
In all arms, patients with recurrent brain metastases may undergo additional stereotactic radiosurgery.
Quality of life is assessed at baseline and at 3, 6, 9, 12, 18, and 24 months.
Patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
Studietype
Intervensjonell
Registrering (Faktiske)
126
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Ottawa, Ontario, Canada, K1Y 4E9
- Ottawa Hospital-Civic Campus
-
-
Quebec
-
Montreal, Quebec, Canada, H2W 1S6
- McGill University Department of Oncology
-
-
-
-
Arizona
-
Scottsdale, Arizona, Forente stater, 85260
- Arizona Oncology Services Foundation
-
Scottsdale, Arizona, Forente stater, 85260
- Scottsdale Health Care-Osborn
-
-
California
-
Burbank, California, Forente stater, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Los Angeles, California, Forente stater, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Pomona, California, Forente stater, 91767
- Pomona Valley Hospital Medical Center
-
-
Colorado
-
Grand Junction, Colorado, Forente stater, 81501
- Saint Mary's Hospital and Regional Medical Center
-
-
Delaware
-
Newark, Delaware, Forente stater, 19718
- Christiana Care Health System-Christiana Hospital
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32207
- Baptist MD Anderson Cancer Center
-
Jacksonville, Florida, Forente stater, 32258
- Baptist Medical Center South
-
Jacksonville, Florida, Forente stater, 32207
- Integrated Community Oncology Network-Southside Cancer Center
-
Jacksonville Beach, Florida, Forente stater, 32250
- Integrated Community Oncology Network-Florida Cancer Center Beaches
-
Miami, Florida, Forente stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orange Park, Florida, Forente stater, 32073
- 21st Century Oncology-Orange Park
-
Orlando, Florida, Forente stater, 32806
- UF Cancer Center at Orlando Health
-
Palatka, Florida, Forente stater, 32177
- 21st Century Oncology-Palatka
-
Panama City, Florida, Forente stater, 32401
- Bay Medical Center
-
Saint Augustine, Florida, Forente stater, 32086
- Integrated Community Oncology Network-Flager Cancer Center
-
Tallahassee, Florida, Forente stater, 32308
- Tallahassee Memorial HealthCare
-
-
Georgia
-
Columbus, Georgia, Forente stater, 31904
- John B Amos Cancer Center
-
-
Idaho
-
Boise, Idaho, Forente stater, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Arlington Heights, Illinois, Forente stater, 60005
- Northwest Community Hospital
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University
-
Harvey, Illinois, Forente stater, 60426
- Ingalls Memorial Hospital
-
Springfield, Illinois, Forente stater, 62702
- Saint John's Hospital
-
-
Indiana
-
Fort Wayne, Indiana, Forente stater, 46805
- Parkview Hospital Randallia
-
Hammond, Indiana, Forente stater, 46320
- Franciscan Saint Margaret Health-Hammond Campus
-
Indianapolis, Indiana, Forente stater, 46202
- IU Health Methodist Hospital
-
-
Iowa
-
Dubuque, Iowa, Forente stater, 52001
- Finley Hospital
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40207
- Norton Suburban Hospital and Medical Campus
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21201
- University of Maryland/Greenebaum Cancer Center
-
Baltimore, Maryland, Forente stater, 21229
- Saint Agnes Hospital
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- University Of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, Forente stater, 48201
- Wayne State University/Karmanos Cancer Institute
-
Kalamazoo, Michigan, Forente stater, 49007
- West Michigan Cancer Center
-
-
Minnesota
-
Burnsville, Minnesota, Forente stater, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Forente stater, 55433
- Mercy Hospital
-
Edina, Minnesota, Forente stater, 55435
- Fairview-Southdale Hospital
-
Fridley, Minnesota, Forente stater, 55432
- Unity Hospital
-
Minneapolis, Minnesota, Forente stater, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Forente stater, 55455
- University of Minnesota/Masonic Cancer Center
-
Robbinsdale, Minnesota, Forente stater, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Forente stater, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Cloud, Minnesota, Forente stater, 56303
- Saint Cloud Hospital
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Louis Park, Minnesota, Forente stater, 55416
- Metro Minnesota Community Oncology Research Consortium
-
Saint Paul, Minnesota, Forente stater, 55102
- United Hospital
-
Waconia, Minnesota, Forente stater, 55387
- Ridgeview Medical Center
-
-
Missouri
-
Saint Louis, Missouri, Forente stater, 63110
- Saint Louis University Hospital
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89106
- Nevada Cancer Research Foundation CCOP
-
Reno, Nevada, Forente stater, 89502
- Renown Regional Medical Center
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Red Bank, New Jersey, Forente stater, 07701
- Riverview Medical Center/Booker Cancer Center
-
Sparta, New Jersey, Forente stater, 07871
- Sparta Cancer Treatment Center
-
-
New York
-
Rochester, New York, Forente stater, 14642
- University of Rochester
-
-
North Carolina
-
Asheville, North Carolina, Forente stater, 28801
- Mission Hospital-Memorial Campus
-
-
Ohio
-
Akron, Ohio, Forente stater, 44304
- Summa Akron City Hospital/Cooper Cancer Center
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
-
Oklahoma
-
Tulsa, Oklahoma, Forente stater, 74136
- Natalie Warren Bryant Cancer Center at Saint Francis
-
-
Pennsylvania
-
Drexel Hill, Pennsylvania, Forente stater, 19026
- Delaware County Memorial Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Forente stater, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Forente stater, 19103
- Radiation Therapy Oncology Group
-
West Reading, Pennsylvania, Forente stater, 19611
- Reading Hospital
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Knoxville, Tennessee, Forente stater, 37916
- Thompson Cancer Survival Center
-
-
Texas
-
Arlington, Texas, Forente stater, 76012
- Arlington Cancer Center
-
Dallas, Texas, Forente stater, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Galveston, Texas, Forente stater, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, Forente stater, 77030
- M D Anderson Cancer Center
-
-
Utah
-
Murray, Utah, Forente stater, 84107
- Intermountain Medical Center
-
Ogden, Utah, Forente stater, 84403
- McKay-Dee Hospital Center
-
Salt Lake City, Utah, Forente stater, 84112
- Huntsman Cancer Institute/University of Utah
-
Salt Lake City, Utah, Forente stater, 84143
- LDS Hospital
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23507
- Sentara Norfolk General Hospital
-
Richmond, Virginia, Forente stater, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Washington
-
Seattle, Washington, Forente stater, 98101
- Virginia Mason Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Forente stater, 53792
- University of Wisconsin Hospital and Clinics
-
Milwaukee, Wisconsin, Forente stater, 53226
- Froedtert and The Medical College of Wisconsin
-
Racine, Wisconsin, Forente stater, 53405
- Wheaton Franciscan Cancer Care - All Saints
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Histologically confirmed non-small cell lung cancer
One to 3 intraparenchymal brain metastases by contrast-enhanced MRI, meeting the following criteria:
- Well circumscribed tumor(s)
Maximum diameter ≤ 4.0 cm
- If multiple lesions are present and one lesion is at the maximum diameter, the other lesions must not exceed 3.0 cm in maximum diameter
- No metastases within 10 mm of the optic apparatus such that a portion of the optic nerve or chiasm would be included in the high-dose stereotactic radiosurgery boost field
- No metastases in the brainstem, midbrain, pons, or medulla
No prior complete resection of all known brain metastases
- Subtotal resection allowed provided residual disease is ≤ 4.0 cm in maximum diameter
No clinical or radiographic evidence of progression (other than study lesion[s]) within the past month
- Patients with brain metastases at initial presentation do not require 1 month of scans documenting stable disease
Stable extracranial metastases allowed
- No known or pre-existing liver metastases
- No leptomeningeal metastases by MRI or cerebrospinal fluid evaluation
- Synchronous brain metastases at initial diagnosis allowed
- Performance status - Zubrod 0-1
- Hemoglobin ≥ 8 g/dL
- Absolute neutrophil count ≥ 1,000/mm^3
- Platelet count ≥ 100,000/mm^3
- AST < 2 times upper limit of normal (ULN)
- Alkaline phosphatase < 2 times ULN unless due to elevated bone metastases
- Total bilirubin normal
- Lactic dehydrogenase < 2 times ULN
- Creatinine < 1.5 times ULN
No clinically active interstitial lung disease
- Chronic stable asymptomatic radiographic changes allowed
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- Neurologic function status 0-2
- No other major medical illness or psychiatric impairment that would preclude study participation
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to erlotinib or temozolomide
- No concurrent immunotherapy
- No concurrent biologic therapy, excluding growth factors and epoetin alfa
- No prior temozolomide or erlotinib
No other concurrent chemotherapy during study radiotherapy
Other concurrent chemotherapy allowed after study radiotherapy, except for the following:
- Temozolomide or erlotinib (arm I only)
- Erlotinib (arm II only)
- Temozolomide (arm III only)
- No prior cranial radiotherapy
- No concurrent intensity-modulated radiotherapy
Concurrent radiotherapy to painful bone lesions allowed
- No concurrent radiotherapy to more than 15% of bone marrow
- No other concurrent therapy for brain metastases unless a recurrence is detected
- More than 30 days since prior investigational drugs
No concurrent enzyme-inducing antiepileptic drugs including, but not limited to, any of the following (for patients randomized to receive erlotinib):
- Phenytoin
- Carbamazepine
- Rifampin
- Phenobarbital
- Primidone
- Oxcarbazepine
- No other concurrent investigational drugs
- No concurrent Hypericum perforatum (St. John's wort)
- No drugs that alter gastric pH (e.g., proton pump inhibitors or H2 antagonists) within 4 hours after erlotinib administration (arm III patients only)
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Arm I
Patients undergo whole brain radiotherapy (WBRT) once daily on days 1-5, 8-12, and 15-19.
Within 14 days after completion of WBRT, patients undergo stereotactic radiosurgery.
|
Patients undergo radiation therapy once daily for approximately 3 weeks
Andre navn:
Patients undergo surgery after radiation therapy
Andre navn:
|
|
Eksperimentell: Arm II
Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral temozolomide once daily on days 1-21.
Beginning 4 weeks after completion of WBRT, patients may receive oral temozolomide alone once daily on days 1-5.
Treatment with temozolomide repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Gis muntlig
Andre navn:
Patients undergo radiation therapy once daily for approximately 3 weeks
Andre navn:
Patients undergo surgery after radiation therapy
Andre navn:
|
|
Eksperimentell: Arm III
Patients undergo WBRT and stereotactic radiosurgery as in arm I. Beginning on the first day of WBRT, patients receive oral erlotinib once daily for up to 6 months.
|
Gis muntlig
Andre navn:
Patients undergo radiation therapy once daily for approximately 3 weeks
Andre navn:
Patients undergo surgery after radiation therapy
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall Survival
Tidsramme: From randomization to date of death or last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
Survival time is defined as time from randomization to date of death from any cause and estimated by the Kaplan-Meier method.
Patients last known to be alive are censored at date of last contact.
|
From randomization to date of death or last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Rate of CNS Progression (One Year)
Tidsramme: From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
CNS progression is defined as any increase in perpendicular bi-dimensional tumor area for any of the 1-3 tracked brain metastases, by any amount, or the appearance of any new brain metastasis on a follow-up MRI (SRS planning scan will not be used to evaluate CNS progression).
For lesions smaller than 1 cm in maximum diameter, a maximum increase of 50% in perpendicular bi-dimensional treatment area is necessary to score as progression.
This caveat is included to account for potential variability in measurement, which is most susceptible to proportionate errors at smaller sizes.
For greater than 1 cm lesions, the definition uses a 25% rule for change.
Rates of CNS progression estimated by the cumulative incidence method, with death treated as a competing risk.
|
From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
|
Quality-adjusted Survival as Measured by EuroQol 5-dimension Instrument
Tidsramme: From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
Quality-adjusted life years (QALY) incorporate the societal-based utilities of health states into expected life years for a health condition.
The QALY model is QALY(h,y) where h is a health state and y is the years of life.
Higher quality-adjusted life year values represent a better outcome.
A patient's health state will be determined from the index score of the EQ-5D-5L patient questionnaire.The EQ-5D-5L is a 2-part self-assessment questionnaire, a 5-item index score and a visual analogue scale, but only the index score is used for quality-adjusted survival.
The index score has 5 items (mobility, self care, usual activities, pain/discomfort, anxiety/depression) each with 5 problem levels (1-none to 5-extreme).
The 5-item index score is transformed into a utility score between 0 (worst health state) and 1 (best health state).
|
From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
|
Change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) Score at 3 Months
Tidsramme: From randomization to three months.
|
The Functional Assessment of Cancer Therapy-Brain (FACT-Br) is a 19-item self-report instrument designed to measure multidimensional quality of life in patients with brain cancer.
It is to be administered with the FACT-General.
There are 5 responses options, with 0=Not a lot and 4=Very much.
All items are added together to obtain a total score, which ranges from 0 to 76. Certain items must be reversed before it is added by subtracting the response from 4. It requires at least 50% of the items to be completed while the overall response rate of the FACT-Br including the FACT-G must be greater than 80%.
If items are missing, the subscale scores can be prorated.
A higher score indicates better QOL.
A change of 5 points will be considered a minimal clinically meaningful change.
Change from baseline at three months (3 month score - baseline score) will be categorized as improvement if increased, stable if no change, or deterioration if decreased.
|
From randomization to three months.
|
|
Change in Performance Status at Six Months
Tidsramme: From randomization to six months.
|
Compared between two treatment arms using a two-group chi-squared test.
Zubrod score will be collected at baseline and follow-up.
The Zubrod performance score runs from 0 to 5, with 0 denoting perfect health and 5 death.
Change from baseline is calculated as 6-month value - baseline value.
Patients with a baseline score who have died by six months will be included in the analysis with a score of 5 at six months.
|
From randomization to six months.
|
|
Change in Steroid Dependence at Six Months
Tidsramme: From randomization to six months.
|
Daily steroid dose will be collected at baseline and follow-up, as one of the following: 0-4 mg, >4 to ≤ 8 mg, >8 to ≤12 mg, and >12 mg.
Change from baseline at six months will be evaluated to have decreased, remained stable, or increased, based on these categories.
|
From randomization to six months.
|
|
Cause of Death (Neurologic vs Other)
Tidsramme: From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
Patients were considered to have died neurologic deaths (coded as "Brain Metastases") if they had stable systemic disease and progressive neurologic disease consisting of expanding intracranial masses, CNS hemorrhages, hydrocephalus resulting in herniation or fulminant meningeal carcinomatosis.
|
From randomization to last follow-up, up to 48.1 months. Analysis occurs after all patients have been potentially followed for 9 months.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Paul Sperduto, Radiation Therapy Oncology Group
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
6. oktober 2004
Primær fullføring (Faktiske)
14. juni 2011
Studiet fullført (Faktiske)
1. april 2012
Datoer for studieregistrering
Først innsendt
9. november 2004
Først innsendt som oppfylte QC-kriteriene
8. november 2004
Først lagt ut (Anslag)
9. november 2004
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
9. mars 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
9. februar 2018
Sist bekreftet
1. februar 2018
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hjernesykdommer
- Sykdommer i sentralnervesystemet
- Sykdommer i nervesystemet
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer etter nettsted
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Neoplasmer i sentralnervesystemet
- Neoplasmer i nervesystemet
- Neoplasmer
- Lungeneoplasmer
- Karsinom, ikke-småcellet lunge
- Neoplasmer i hjernen
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Proteinkinasehemmere
- Erlotinib hydroklorid
- Temozolomid
Andre studie-ID-numre
- NCI-2009-00720 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- U10CA021661 (U.S. NIH-stipend/kontrakt)
- CDR0000389490
- RTOG 0320 (Annen identifikator: Radiation Therapy Oncology Group)
- RTOG-0320 (Annen identifikator: CTEP)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .